Intralesional methotrexate treatment for keratoacanthoma tumors: A retrospective case series

Journal of Cutaneous Medicine and Surgery

Volumn 16, Issue 3, 2012, Pages 212-217

  Aubut, Nicolas ^a,b,c   Alain, Jimmy ^a,b,c   Claveau, Joed̈l ^a,b,c  

^a LAVAL UNIVERSITY   (Canada)

^b Centre de Recherche Dermatologique du Quebec Metropolitain   (Canada)

^c Clinique Dermatologique Joël Claveau   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE;

ADULT; AGED; ARTICLE; CASE STUDY; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KERATOACANTHOMA; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; FEMALE; HUMANS; INJECTIONS, INTRALESIONAL; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84864217083     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347541201600316     Document Type: Article

References (27)

1. Beham A, Regauer S, Soyer HP, Beham-Schmid C. Keratoacanthoma: a clinically distinct variant of well-differentiated squamous cell carcinoma. Adv Anat Pathol 1998;5:269-80, doi:10.1097/00125480-199809000-00001.
2. Manstein CH, Frauenhoffer CJ, Besden JE. Keratoacanthoma: is it a real entity? Ann Plast Surg 1998;40:469-72, doi:10.1097/00000637-199805000-00004. (Pubitemid 28215516)
3. Rapini RP. Practical dermatopathology. New York: Elsevier Mosby; 2005.
4. Wilsmann-Theis D, Wenzel J, Betten HH, et al. A rapidly growing squamous cell carcinoma or keratoacanthoma or both? Acta Derm Venereol 2007;87:447-8, doi:10.2340/00015555-0294. (Pubitemid 351373433)
5. Goldenhersh MA, Olsen TG. Invasive squamous cell carcinoma initially diagnosed as a giant keratoacanthoma. J Am Acad Dermatol 1984;10:372-8, doi:10.1016/S0190-9622(84)80010-9. (Pubitemid 14181968)
6. Cribier B. Keratoacanthoma? Better to say "squamous cell carcinoma, keratoacanthoma type." Ann Dermatol Venereol 2008;135:541-6, doi:10.1016/j.annder.2008.03.001.
7. Mandrell JC, Santa Cruz D. Keratoacanthoma: hyperplasia, benign neoplasm, or a type of squamous cell carcinoma? Semin Diagn Pathol 2009;26:150-63, doi:10.1053/j.semdp.2009.09.003.
8. Ko CJ. Keratoacanthoma: facts and controversies. Clin Dermatol 2010;28:254-61, doi:10.1016/j.clindermatol.2009.06.010.
9. Annest NM, VanBeek MJ, Arpey CJ, Whitaker DC. Intralesional methotrexate treatment for keratoacanthoma tumors: a retrospective study and review of the literature. J Am Acad Dermatol 2007;56:989-93, doi:10.1016/j.jaad.2006.12.017. (Pubitemid 46720214)
10. Larson PO. Keratoacanthomas treated with Mohs' micrographic surgery: a review of forty-three cases. J Am Acad Dermatol 1987;16:1040-4, doi:10.1016/S0190-9622(87)70134-0. (Pubitemid 17073139)
11. Wong WY, Kolbusz RV, Goldberg LH, Guana A. Treatment of recurrent keratoacathoma with oral isotretinoin. Int J Dermatol 1994;33:579-83, doi:10.1111/j.1365-4362.1994.tb02902.x. (Pubitemid 24255809)
12. Goldschmidt H, Sherwin WK. Radiation therapy of giant aggressive keratoacanthomas. Arch Dermatol 1993;129:1162-5, doi:10.1001/archderm.1993. 01680300090014. (Pubitemid 23272097)
13. Reymann F. Treatment of keratoacanthomas with curettage. Dermatologica 1997;155:90-6, doi:10.1159/000250961.
14. Nedwich JA. Evaluation of curettage and electrodesiccation in treatment of keratoacanthoma. Australas J Dermatol 1991;32:137-41, doi:10.1111/j.1440- 0960.1991.tb01777.x.
15. Dendorfer M, Oppel T, Wollenberg A, Prinz JC. Topical treatment with imiquimod may induce regression of facial keratoacanthoma. Eur J Dermatol 2003;13:80-2.
16. Parker CM, Hanke CW. Large keratoacanthomas in difficult locations treated with intralesional 5-fluorouracil. J Am Acad Dermatol 1986;14:770-7, doi:10.1016/S0190-9622(86)70092-3. (Pubitemid 16113969)
17. Melton JL, Nelson BR, Stough DB, et al. Treatment of keratoacanthomas with intralesional methotrexate. J Am Acad Dermatol 1991;25:1017-23, doi:10.1016/0190-9622(91)70301-H.
18. Hurst LN, Gan BS. Intralesional methotrexate in keratoacanthoma of the nose. Br J Plast Surg 1995;48:243-6, doi:10.1016/0007-1226(95)90010-1.
19. Cuesta-Romero C, de Grado-Pena J. Intralesional methotrexate in solitary keratoacanthoma. Arch Dermatol 1998;134:513-4, doi:10.1001/archderm.134.4.513.
20. Remling R, Mempel M, Schnopp N, et al. Intralesional methotrexate injection: an effective time and cost saving therapy alternative in keratoacanthomas that are difficult to treat surgically. Hautarzt 2000;51:612-4, doi:10.1007/s001050051180. (Pubitemid 30629230)
21. Spieth K, Gille J, Kaufmann R. Intralesional methotrexate as effective treatment in solitary giant keratoacanthoma of the lower lip. Dermatology 2000;200:317-9, doi:10.1159/000018395. (Pubitemid 30451580)
22. Richard MA, Gachon J, Choux R, et al. Treatment of keratoacanthoma with intralesional methotrexate injections. Ann Dermatol Venereol 2000;127:1097.
23. de Visscher JG, van der Wal KG, Blanken R, Willemse F. Treatment of giant keratoacanthoma of the lower lip with intralesional methotrexate: a case report. J Oral Maxillofac Surg 2002;60:93-5, doi:10.1053/joms.2002.29083. (Pubitemid 34056301)
24. Cohen PR, Schulze KE, Teller CF, Nelson BR. Intralesional methotrexate for keratoacanthoma of the nose. Skinmed 2005;4:393-5, doi:10.1111/j.1540-9740. 2005.03866.x.
25. Goebeler M, Lurz C, Kolve-Goebeler ME, Brocker EB. Pancytopenia after treatment of keratoacanthoma by a single lesional methotrexate infiltration. Arch Dermatol 2001;137:1104-5. (Pubitemid 32756475)
26. Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol 2005;4:648-51.
27. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991;25:306-18, doi:10.1016/0190-9622(91)70199-C.